resTORbio Inc (TORC):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8219)
◆英語タイトル:resTORbio Inc (TORC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8219
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
resTORbio Inc (resTORbio) a subsidiary of Puretech Health plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medicines for the treatment of aging-related diseases. Its pipeline product candidate RTB101, an orally administered, small molecule, potent TORC1 inhibitor alone or in combination with everolimus used for the treatment of respiratory tract infections, autophagy-related diseases. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems. resTORbio is headquartered in Boston, Massachusetts, the US.

resTORbio Inc (TORC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
resTORbio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
resTORbio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
resTORbio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
resTORbio Raises USD40 Million in Series B Financing 10
resTORbio Raises USD25 Million in Series A Financing 12
Equity Offering 13
resTORbio Raises USD97.8 Million in IPO of Shares 13
resTORbio Inc – Key Competitors 14
resTORbio Inc – Key Employees 15
resTORbio Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Aug 09, 2018: resTORbio reports second quarter 2018 financial results 17
May 10, 2018: resTORbio Reports First Quarter 2018 Financial Results 19
Mar 29, 2018: resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results 20
Corporate Communications 21
Jan 03, 2018: PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors 21
Jan 03, 2018: resTORbio Appoints Lynne Sullivan to Its Board of Directors 22
Dec 11, 2017: resTORbio Appoints Paul Fonteyne to its Board of Directors 23
Product News 24
12/11/2017: resTORbio Appoints Paul Fonteyne to its Board of Directors 24
03/19/2018: resTORbio Announces Formation of Clinical Advisory Board 25
Clinical Trials 27
Jul 25, 2018: PureTech Health Affiliate resTORbio Announces Positive Topline Results in Phase 2b Trial of RTB101 27
Jul 11, 2018: resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older 29
May 22, 2018: resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition 30
May 09, 2018: resTORbio Completes Dosing of Patients in Phase 2b Study to Reduce the Incidence of Respiratory Tract Infections in the Elderly 31
Nov 20, 2017: PureTech’s resTORbio Advances Immunotherapy Candidate for Aging-Related Conditions Following Recommendation from Independent Data Monitoring Committee 32
May 09, 2017: PureTech Health Announces Initiation of Phase 2b mTORC1 Inhibitors Study in Elderly Patients at Increased Risk of Respiratory Tract Infections 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
resTORbio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
resTORbio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
resTORbio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
resTORbio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
resTORbio Raises USD40 Million in Series B Financing 10
resTORbio Raises USD25 Million in Series A Financing 12
resTORbio Raises USD97.8 Million in IPO of Shares 13
resTORbio Inc, Key Competitors 14
resTORbio Inc, Key Employees 15

List of Figures
resTORbio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
resTORbio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
resTORbio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ resTORbio Inc (TORC):製薬・医療:M&Aディール及び事業提携情報(resTORbio Inc (TORC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆